EcoDrugPlus

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSBSLG00000011445
Gene Symbol: HTR1B
3 Cross references
178 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSBSLG00000010936
Gene Symbol: HTR1E
3 Cross references
147 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSBSLG00000015230
Gene Symbol: HTR2A
3 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a-Like

Ensembl ID : ENSBSLG00000003087
Gene Symbol: LOC114847733
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSBSLG00000006971
Gene Symbol: HTR2B
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSBSLG00000006334
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSBSLG00000006276
Gene Symbol: HTR3B
3 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSBSLG00000016615
Gene Symbol: HTR4
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSBSLG00000001206
Gene Symbol: HTR5A
3 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSBSLG00000014052
Gene Symbol: HTR7
2 Cross references
197 Possible Orthologues:

60s Ribosomal Protein L10

Ensembl ID : ENSBSLG00000008233
Gene Symbol: LOC114859297
3 Cross references
407 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSBSLG00000014960
Gene Symbol: LOC114859914
3 Cross references
334 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).